Australia · Delayed Price · Currency is AUD Medical Developments International Earnings Call Transcripts
Fiscal Year 2026
-
Group revenue grew 8% year-over-year, led by 18% growth in pain management, while respiratory declined 10%. Underlying earnings and cash flow improved, with strong progress on pediatric approvals in Europe and margin initiatives. Second half earnings are expected to be lower due to seasonal respiratory softness.
Fiscal Year 2025
-
The AGM highlighted strong FY 2025 financial recovery, board renewal, and a focus on accelerating Penthrox adoption and U.S. respiratory growth. All resolutions passed, with shareholders engaging on governance, market challenges, and director recruitment.
-
FY25 saw strong revenue and margin growth, with significant improvements in cash flow and profitability. Strategic initiatives, including expanded pediatric approval and new distribution partnerships, set the stage for accelerated volume growth, though FY26 EBIT may soften due to upfront investments.
-
HY25 saw a 33% revenue increase and a return to profitability, driven by strong growth in pain management and respiratory segments, improved margins, and disciplined cost control. H2 earnings are expected to be lower due to delivery timing and FX, but full-year EBIT will be up on FY24.
Fiscal Year 2024
-
The AGM highlighted improved financial trends, cost reductions, and a sharpened focus on core business profitability. Strategic expansion in hospitals and international markets continues, while U.S. entry is paused pending partnership and funding clarity. Shareholders supported most resolutions, with increased placement capacity falling short of approval.
-
FY 2024 delivered improved margins, earnings, and cash flow, with strong growth in Penthrox volumes in Australia and respiratory revenues in the U.S. Strategic initiatives and a capital raise position the company for further margin gains and positive cash flow in FY 2025.
-
A AUD 10 million capital raise will fund targeted growth and strengthen the balance sheet, supporting a strategy focused on disciplined investment, medical engagement, and leveraging new clinical data. Revenue and cash flow have improved, with strong growth expected from Penthrox and respiratory products.